Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05370300 · ClinicalTrials.gov registry record
SNAPS Breast Cancer Patient Study Breast Cancer Patients
A clinical trial, sponsored by Immunis.AI.
- Not yet
- Registry status
- 500
- Enrollment target
NCT05370300: Clinical Trial study, sponsored by Immunis.AI.
NCT05370300 is a clinical trial that has not yet begun recruiting, run by Immunis.AI. The registered enrollment target is 500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05370300 has not yet begun recruiting, sponsored by Immunis.AI.
- NOT YET RECRUITING
- Registry status
- 500 participants
- Enrollment target
Study Summary
Differential immunogenomic signatures from peripheral blood CD14 (phagocytic) and CD2 (non-phagocytic) cells have been associated with multiple cancers and disease states. In particular several large clinical studies at Immunis.AI have demonstrated robust immunogenomic signatures in early-stage prostate cancer. Immunis.AI therefore hypothesizes that a peripheral blood immunogenomic signature will identify patients with various stages of breast cancer from healthy negative controls.
Primary Outcome
To determine if differential gene expression between peripheral blood phagocytic and non-phagocytic immune cells can distinguish breast cancer patients from cancer-negative controls.
Interventions
- DIAGNOSTIC_TEST Blood test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-09-01 |
| Est. Completion | 2027-12-31 |
What is known before NCT05370300 opens enrollment
NCT05370300 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Blood test is the first listed.
NCT05370300 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05370300 about?
NCT05370300 is a clinical study titled "SNAPS Breast Cancer Patient Study Breast Cancer Patients". Differential immunogenomic signatures from peripheral blood CD14 (phagocytic) and CD2 (non-phagocytic) cells have been associated with multiple cancers and disease states. In particular several large clinical studies at Immunis.AI have demonstrated robust immunogenomic signatures in early-stage pros...
What is the current status of trial NCT05370300?
This trial is currently not yet recruiting. The enrollment target is 500 participants. The study started on 2025-09-01. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT05370300?
The interventions under investigation include: Blood test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05370300?
This trial is sponsored by Immunis.AI, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI